Skip Navigation


Annals of Oncology Advance Access originally published online on March 31, 2005
Annals of Oncology 2005 16(5):786-792; doi:10.1093/annonc/mdi148
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/5/786    most recent
mdi148v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (21)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hagenbeek, A.
Right arrow Articles by Lewington, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hagenbeek, A.
Right arrow Articles by Lewington, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Report of a European consensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevalin®) in lymphoma

A. Hagenbeek1,* and V. Lewington2

1 Department of Haematology, University Medical Center Utrecht, The Netherlands; 2 Department of Nuclear Medicine and PET, Royal Marsden Hospital, Sutton, UK

* Correspondence to: Dr A. Hagenbeek, University Medical Center Utrecht, Department of Haematology (GO3.647), PO Box 85500, Heidelberglaan 100, Utrecht, 3508 GA, The Netherlands. Tel: +31-30-250-7769; Fax: +31-30-251-1893; Email: a.hagenbeek{at}azu.nl

Background:: Non-Hodgkin's lymphoma (NHL) comprises a group of related haematological malignancies, predominantly of B-cell origin, which have been described as indolent or aggressive according to their clinical course. Standard treatment for indolent NHL consists of conventional chemotherapy, but, although long-term remissions may occur, most patients will die of their disease. Radioimmunotherapy (RIT) is a novel modality for treating indolent NHL, using monoclonal antibodies to target tumour cells with systemic, low-dose radiation. 90Y-Ibritumomab tiuxetan (Zevalin®; Schering AG, Berlin, Germany), the first RIT approved for use in relapsed/refractory indolent NHL, comprises the murine anti-CD20 monoclonal antibody ibritumomab, covalently linked to the high-energy beta-emitter, yttrium-90, by the chelator, tiuxetan.

Materials and methods:: A multidisciplinary consensus workshop of European clinicians who had taken part in clinical trials of 90Y-ibritumomab tiuxetan was convened to develop recommendations for the clinical preparation and administration of 90Y-ibritumomab tiuxetan in Europe. The workshop was held in anticipation of European Medicines Agency approval of this agent, which was gained in 2004 for adult patients with rituximab-relapsed or refractory CD20+ follicular B-cell NHL.

Results and conclusions:: This article summarises the consensus recommendations developed for haemato-oncologists.

Key words: guidelines, haematologist, lymphoma, oncologist, 90Y-ibritumomab tiuxetan


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
Y. Terui, Y. Mishima, N. Sugimura, K. Kojima, T. Sakurai, Y. Mishima, R. Kuniyoshi, A. Taniyama, M. Yokoyama, S. Sakajiri, et al.
Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma
Clin. Cancer Res., April 1, 2009; 15(7): 2523 - 2530.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.